...A. We have -- right now, we have an approved product INPEFA, sotagliflozin. B. Zynquista is sotagliflozin, which we're going to be resubmitting for type 1 diabetes approval around the middle of this year. C. Going further back into our pipeline, LX9211 addresses a novel target, Adapter Associated Kinase 1 for neuropathic pain, we have a study ongoing that is a dose optimization Phase IIb study that we -- has been enrolling patients. D. We expect to complete enrollment this year, and we're expecting data at beginning of -- or the first half of next year for that program. E. And then just recently announced at our Investor Day about a month ago is LX9851, which addresses another novel target, ACSL5. F. As I mentioned, we're about to resubmit the NDA for Zynquista around the middle of this year. G. That's a study that we just launched this year and was, among other things and has been supported by the capital that we raised earlier this year, $250 million of capital that allows us to bring...
